MarketPulse
L

$LLY

81 articles found
45 positive
6 negative
29 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BIO-Europe Spring 2026 Poised for Record Dealmaking as 3,700+ Leaders Convene

BIO-Europe Spring 2026 in Lisbon expects 3,700+ attendees, 20,000+ meetings, and robust partnering activity as global biopharma industry seeks strategic deals and investment opportunities.
JNJLLYNVOGSKTEVAventure capitalLisbon
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Weight-Loss Dominance Faces Pipeline Challengers, But Lead Remains Secure

Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.
LLYNVORHHBYREGNclinical trialsweight loss drugs
Investing.comInvesting.com··Jeffrey Neal Johnson

Eli Lilly's $3B China Bet: Securing GLP-1 Dominance in World's Largest Metabolic Market

Eli Lilly commits $3 billion to decade-long China expansion, targeting 141 million diabetics and 600 million overweight adults amid intense domestic competition.
LLYNVOsupply chainGLP-1 drugs
BenzingaBenzinga··Vandana Singh

Eli Lilly Warns of Unknown Impurity in Compounded Weight Loss Drugs

Eli Lilly warns of unidentified impurity in compounded tirzepatide weight loss drugs mixed with vitamin B12, urging FDA recalls and stricter oversight.
LLYweight loss drugsZepbound
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline
BenzingaBenzinga··Vandana Singh

Eli Lilly Poised to Challenge AstraZeneca in Abivax Bidding War

AstraZeneca has exclusive access to Abivax data until March 23. If it misses deadline, Eli Lilly could rejoin bidding for French biotech valued by 1,600% surge.
LLYAZNABVXacquisitionbiotech
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Oral GLP-1 Drug Could Reshape Weight Loss Market as Novo Nordisk Faces Competition

Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.
LLYNVOpharmaceutical competitionweight-loss drug
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer and Novo Nordisk: Undervalued Pharma Giants Poised for Rebounds

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.
PFELLYNVOclinical trialshealthcare stocks
BenzingaBenzinga··Vandana Singh

Roche's Breast Cancer Drug Falls Short in Pivotal Trial, Stock Drops 5%

Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.
LLYNVORHHBYclinical trial failurePhase 3 trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

GLP-1 Glory or Diversified Dividend? Novo Nordisk vs. Amgen in Weight Loss Race

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.
AMGNLLYNVOclinical trialsmarket share
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Lilly's Valuation Trap vs. Merck's Dividend Appeal: A Tale of Two Pharma Giants

Eli Lilly trades at expensive P/E of 44 with meager 0.6% dividend yield despite GLP-1 success. Merck offers better value at P/E 16 and 2.8% yield with 30+ year dividend track record.
MRKLLYvaluationdividend stocks
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors

Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.
PFELLYNVOGLP-1 drugsgeneric competition
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk Stock Looks Cheap, But Execution Risks Cloud Recovery Outlook

Novo Nordisk stock trades cheap but faces execution headwinds versus Eli Lilly's superior operational performance in the booming GLP-1 market.
LLYNVOweight loss drugspharmaceutical competition
BenzingaBenzinga··Vandana Singh

Pfizer's Weight-Loss Drug Wins China Approval, Intensifying GLP-1 Competition

Pfizer wins NMPA approval for weight-loss drug ecnoglutide in China, achieving 15.4% average weight loss in trials, intensifying competition as Novo Nordisk's Wegovy faces patent expiry.
PFELLYNVOclinical trialweight-loss drug
BenzingaBenzinga··Vandana Singh

Roche's Obesity Drug Falls Short of GLP-1 Rivals in Phase 2 Results

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.
LLYNVORHHBYclinical trial resultsweight loss
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk's Obesity Drug Underperforms Rival Zepbound in Late-Stage Trial

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.
LLYNVOclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Drug Market Poised to Triple to $202B by 2033 Amid Obesity Surge

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.
LLYSNYNVOAZNIVBIYclinical trialsmarket growth
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Market Set to Nearly Triple to $137B by 2030 as Drug Class Expands Beyond Diabetes

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.
AMGNPFELLYNVORHHBY+1weight lossdiabetes treatment
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pharma Giant and Cloud Pioneer Lead Growth Stock Rally Into 2026

Analysts spotlight $LLY's obesity drug dominance and $VEEV's cloud expansion as top growth picks for first half 2026.
LLYVEEVlong-term investingGLP-1 drugs
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks; Analysts Eye Cheaper Alternatives

Eli Lilly trades at premium 44 P/E despite GLP-1 concentration risks. Novo Nordisk and Pfizer offer higher yields and lower valuations.
PFELLYNVOvaluationbiotech